- Home
- APLS vs SWTX Comparison
APLS vs SWTX Comparison
Compare APLS & SWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLS
- SWTX
- Stock Information
- Founded
- APLS 2009
- SWTX 2017
- Country
- APLS United States
- SWTX United States
- Employees
- APLS N/A
- SWTX N/A
- Industry
- APLS Biotechnology: Pharmaceutical Preparations
- SWTX Biotechnology: Pharmaceutical Preparations
- Sector
- APLS Health Care
- SWTX Health Care
- Exchange
- APLS Nasdaq
- SWTX Nasdaq
- Market Cap
- APLS 3.6B
- SWTX 3.0B
- IPO Year
- APLS 2017
- SWTX 2019
- Fundamental
- Price
- APLS $27.52
- SWTX $58.25
- Analyst Decision
- APLS Buy
- SWTX Strong Buy
- Analyst Count
- APLS 18
- SWTX 6
- Target Price
- APLS $46.71
- SWTX $70.83
- AVG Volume (30 Days)
- APLS 1.4M
- SWTX 3.2M
- Earning Date
- APLS 02-28-2025
- SWTX 02-20-2025
- Dividend Yield
- APLS N/A
- SWTX N/A
- EPS Growth
- APLS N/A
- SWTX N/A
- EPS
- APLS N/A
- SWTX N/A
- Revenue
- APLS $715,216,000.00
- SWTX $191,589,000.00
- Revenue This Year
- APLS $97.25
- SWTX $3,475.18
- Revenue Next Year
- APLS $12.68
- SWTX $81.60
- P/E Ratio
- APLS N/A
- SWTX N/A
- Revenue Growth
- APLS 162.10
- SWTX 3417.33
- 52 Week Low
- APLS $24.34
- SWTX $28.21
- 52 Week High
- APLS $71.90
- SWTX $62.00
- Technical
- Relative Strength Index (RSI)
- APLS 38.99
- SWTX 70.71
- Support Level
- APLS $26.84
- SWTX $54.89
- Resistance Level
- APLS $28.59
- SWTX $62.00
- Average True Range (ATR)
- APLS 1.12
- SWTX 4.09
- MACD
- APLS -0.03
- SWTX 1.35
- Stochastic Oscillator
- APLS 18.09
- SWTX 85.90
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
About SWTX SpringWorks Therapeutics Inc.
SpringWorks Therapeutics Inc is a clinical stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing highly prevalent, genetically defined cancers.